. Author manuscript; available in PMC: 2020 Sep 9.

Published in final edited form as: J Am Acad Dermatol. 2020 Feb 14;83(1):172–178. doi: 10.1016/j.jaad.2020.02.020

Table IV.

BP180 and BP230 levels via enzyme-linked immunosorbent assay testing compared with C3d, direct immunofluorescent (DIF), and indirect immunofluorescent (IIF) results

Variable^*	C3d (+) (n = 21))	C3d (−) (n = 30)	P value^*	C3d true positive (N = 20)	C3d false negative (n = 7)	P value^†
BP180	74.9 (34.5, 121.2)	2.8 (1.6, 5.6)	<.0001	76.6 (40.1, 131.1)	5.6 (3.0, 139.7)	.06
BP230	43.3 (6.7, 75.6)	3.4 (1.5, 5.9)	<.0001	51.5 (10.1, 78.4)	12.6 (4.3, 71.8)	.38
	DIF (+) (n = 17)	DIF (−) (n = 34)		DIF true positive (n = 17)	DIF false negative (n = 10)

BP180	86.9 (34.5, 141.0)	3.3 (1.6, 8.8)	<.0001	86.9 (34.5, 141.0)	35.0 (5.6, 73.9)	.08
BP230	59.7 (6.3,75.6)	4.1 (1.5,7.0)	.0021	59.7 (6.3, 75.6)	26.4 (12.6, 60.9)	.76
	IIF (+) (N = 19)	IIF (−)(N=32)		IIF true positive (n = 19)	IIF false negative (n = 8)

BP180	74.9 (22.5, 139.7)	2.8 (1.6, 9.8)	<.0001	74.9 (22.5, 139.7)	32.5 (17.6, 150.1)	.56
BP230	60.9 (12.6, 105.9)	3.5 (1.5, 6.3)	<.0001	60.9 (12.6, 105.9)	12.8 (5.5, 26.4)	.03

Data are presented as the median (interquartile range).

^†

Wilcoxon rank sum test.